Current and future use of dipyridamole in patients with COVID-19
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment. |
|---|---|
| Item Description: | 2588-0519 2618-8473 10.37489/2588-0519-2020-S4-92-95 |